Evogene (EVGN) Operating Income (2012 - 2026)

Evogene has disclosed Operating Income across 15 years of filings, most recently posting -$2.6 million for Q2 2026.

• In Q2 2026, Operating Income rose 1.88% year-over-year to -$2.6 million; the TTM figure through Jun 2026 stood at -$13.6 million (up 9.24% YoY), while the FY2025 annual figure was -$12.0 million, up 36.03% from the prior year.
• Operating Income came in at -$2.6 million for Q2 2026 at Evogene, up from -$3.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$1.4 million in Q2 2024 to a low of -$8.1 million in Q1 2022.
• Average Operating Income over 5 years is -$4.9 million, with a median of -$4.1 million recorded in 2023.
• Year-over-year, Operating Income slumped 101.69% in 2023 and soared 81.88% in 2024.
• Over 5 years, Operating Income stood at -$3.8 million in 2022, then slumped by 101.69% to -$7.6 million in 2023, then surged by 54.38% to -$3.5 million in 2024, then slumped by 49.77% to -$5.2 million in 2025, then jumped by 50.83% to -$2.6 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$2.6 million in Q2 2026, -$3.2 million in Q1 2026, and -$5.2 million in Q4 2025.